![](/img/cover-not-exists.png)
Impact of TP53 and KRAS mutations on cisplatin-based adjuvant chemotherapy in non-small-cell lung cancer
X. Ma, E. Brambilla, J.C. Soria, A. Dunant, A.L. Vataire, P. Hainaut, the IALT-Bio study groupVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)71573-8
File:
PDF, 85 KB
english, 2008